Heart failure concerns cloud Multaq outlook
This article was originally published in Scrip
Executive Summary
Last week, the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted ten to three in favour of approving Sanofi-Aventis’s anti-arrhythmic Multaq (dronedarone) for the treatment of patients with non-permanent atrial fibrillation (scripnews.com, March 19th, 2009). But questions about the use of the product in patients with severe heart failure have cast something of a shadow over what was otherwise excellent news for the company.